These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28327183)

  • 21. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stochastic modeling of drug resistance in cancer.
    Komarova N
    J Theor Biol; 2006 Apr; 239(3):351-66. PubMed ID: 16194548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance.
    Li S; Payne S; Wang F; Claus P; Su Z; Groth J; Geradts J; de Ridder G; Alvarez R; Marcom PK; Pizzo SV; Bachelder RE
    Breast Cancer Res; 2015 Jul; 17(1):91. PubMed ID: 26141457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of cell density and mutations in a model of multidrug resistance in solid tumors.
    Greene J; Lavi O; Gottesman MM; Levy D
    Bull Math Biol; 2014 Mar; 76(3):627-53. PubMed ID: 24553772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticancer drug resistance in primary human brain tumors.
    Bredel M
    Brain Res Brain Res Rev; 2001 Apr; 35(2):161-204. PubMed ID: 11336781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer.
    Sameen S; Barbuti R; Milazzo P; Cerone A; Del Re M; Danesi R
    J Theor Biol; 2016 Jan; 389():263-73. PubMed ID: 26551156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
    Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
    Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding resistance to targeted cancer drugs through loss of function genetic screens.
    Berns K; Bernards R
    Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanisms of drug resistance.
    Longley DB; Johnston PG
    J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrinsic and induced drug resistance mechanisms: in silico investigations at the cellular and tissue scales.
    Liu C; Krishnan J; Xu XY
    Integr Biol (Camb); 2015 Sep; 7(9):1044-60. PubMed ID: 26211533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
    Stover EH; Konstantinopoulos PA; Matulonis UA; Swisher EM
    Clin Cancer Res; 2016 Dec; 22(23):5651-5660. PubMed ID: 27678458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cancer Stem Cells (CSCs) as a Rational Therapeutic Cancer Target, and Screening for CSC-targeting Drugs].
    Mashima T
    Yakugaku Zasshi; 2017; 137(2):129-132. PubMed ID: 28154319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer drug resistance: the central role of the karyotype.
    Duesberg P; Li R; Sachs R; Fabarius A; Upender MB; Hehlmann R
    Drug Resist Updat; 2007; 10(1-2):51-8. PubMed ID: 17387035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of an in vitro chemotherapy to avoid resistant tumours.
    Carrère C
    J Theor Biol; 2017 Jan; 413():24-33. PubMed ID: 27864095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An elementary approach to modeling drug resistance in cancer.
    Tomasetti C; Levy D
    Math Biosci Eng; 2010 Oct; 7(4):905-18. PubMed ID: 21077714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.
    Yang X; Yang Y; Tang S; Tang H; Yang G; Xu Q; Wu J
    J Pharmacol Sci; 2015 Sep; 129(1):65-71. PubMed ID: 26390965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do beta-tubulin mutations have a role in resistance to chemotherapy?
    Berrieman HK; Lind MJ; Cawkwell L
    Lancet Oncol; 2004 Mar; 5(3):158-64. PubMed ID: 15003198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 20(S)-protopanoxadiol derivative overcomes multi-drug resistance by antagonizing ATP-binding cassette subfamily B member 1 transporter function.
    Chen G; Liu J; Chen W; Xu Q; Xiao M; Hu L; Mao L; Wang X
    Oncotarget; 2016 Feb; 7(8):9388-403. PubMed ID: 26824187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of acquired resistance to targeted cancer therapies.
    Lackner MR; Wilson TR; Settleman J
    Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.